Clareo Health | A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
A Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Inc
All participants will be randomized to one of two imaging sequences: rest/stress SPECT on Day 1 followed by stress/rest MDCT on Day 2 or stress/rest MDCT on Day 1 followed by rest/stress SPECT on Day 2. All stress scans will involve the injection of regadenoson as the pharmacologic stress agent.
Age
45–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male subjects must be ≥ 45 years of age
Female subjects must be ≥ 50 years of age
Subject has met at least one of the following three criteria:
* has a suspected (clinical impression) or known diagnosis of coronary artery disease (CAD) with typical angina that has been referred from nuclear cardiology lab schedule or cardiac computed tomography (CT) schedule
* has stable symptoms with possible elective catheterization procedure scheduled and where further imaging may be beneficial;
* has known CAD from a previous invasive coronary angiography (ICA) performed more than 12 weeks prior to screening who now present with new cardiac symptoms
Subject has been referred for a clinically indicated myocardial perfusion imaging procedure or Cardiac CT procedure for suspected moderate or high risk CAD
Subject must abstain from eating and drinking 30 minutes prior and 30 minutes post study drug administration
Subject must abstain from smoking 3 hours prior and 8 hours post study drug administration
Subject must abstain from any intake of methylxanthine-containing foods and beverages within 12 hours prior to Day 1 visit through the Day 3 Follow-Up Visit, as these foods may alter regadenoson effects. Subject is able to safely abstain from theophylline use for 12 hours prior to study drug administration
You may not be if
Subject is concurrently participating in another drug study or has received an investigational drug within 30 days prior to Screening
Subject has a history of a clinically significant illness (other than CAD), medical condition, or laboratory abnormality, which would preclude participation in the study
Subject has renal dysfunction demonstrated by a glomerular filtration rate (GFR) \< 45 mL/min (calculated using Cockroft-Gault formula Note: Subjects with a GFR 45-60 mL/min will undergo a hydration procedure
Female subject who is pregnant, lactating or of childbearing potential that refuses to use a medically acceptable form of contraception until the Telephone Follow up Visit is complete
Female subject has a positive pregnancy test prior to randomization
Subject has a history of second or third degree heart block or sinus node dysfunction unless the subject has a functioning pacemaker
Subject has symptomatic hypotension (temporary and reversible conditions that no longer exist are allowed)
Subject is allergic or intolerant to aminophylline, nitroglycerin or metoprolol
Subject is allergic or intolerant to regadenoson or any of its excipients
Subject is unable or unwilling to comply with the procedure schedule
Subject has previously enrolled in this study or was enrolled in another regadenoson study sponsored by Astellas
Subject has atrial fibrillation or significant arrhythmias which may result in decreased image quality for the imaging studies (CT and SPECT)
Subject has high heart rate (\> 65 beats per minute) and contra-indications to administer beta-blockers (severe chronic obstructive pulmonary disease (COPD) or asthma, second and third degree atrioventricular block)
